At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Commentary|Articles|June 17, 2026
ADA 2026: Key Pharmacotherapy Advances in Type 1 and Type 2 Diabetes
Fact checked by: Gillian McGovern, Editor, Ron Panarotti
The ADA Scientific Sessions highlighted important advances across the diabetes treatment landscape.
Advertisement
Advertisement
The 86th American Diabetes Association (ADA) Scientific Sessions, held June 5 through 8, 2026, in New Orleans, Louisiana, highlighted important advances across the diabetes treatment landscape. Although obesity therapeutics and diabetes technology generated considerable attention, several presentations focused specifically on therapies for type 1 diabetes (T1D) and type 2 diabetes (T2D).
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
Advertisement
Advertisement